EN DE
Watch PureTech Health plc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PureTech Health plc (PRTC) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of PureTech Health plc stock £0.83, price £1.26, that is 34.1% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · Based in US · ISIN GB00BY2Z0H74

PH PureTech Health plc logo Thin data Nov 10, 2026

PureTech Health plc

PRTC · LSE
Expensive, weak quality

Our calculation puts a fair price 34% below what the stock costs today.

Highly profitable · 33.2% net margin (TTM)
Low debt
Ranks above peers (7/9)
Last quarter vs. a year ago: revenue +92%, profit +62%.
Quality 40/100
Mixed Growth (revenue 5y −10.6 %/yr in USD)
Fair value £0.8300 · Overvalued
Negative free cash flow
Narrow moat 38/100 · thin data
Thin data
Estimate
Watch PureTech Health plc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£3.67 £1.03 Fair Value £0.8300 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £1.03 – £3.67 · fair‑value band £0.6200 – £1.04 · the £1.26 price screens above the £0.8300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow PureTech Health in your weekly email

Every Wednesday you see whether PureTech Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

Show moreShow less

It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.

The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions.

In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage.

PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.

Stock analysis

PureTech Health plc (PRTC) currently trades at £1.26, while our estimate is £0.8300, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.6200 (bear) to £1.04 (bull), the price of £1.26 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2019: revenue and profit before it include the divested business. Growth is measured afresh from 2019.

PureTech Health plc reported revenue of $4.8M in FY2025 versus $10.0M in FY2021, a compound −16.9%/yr. Reported net income was −$112M in FY2025.

Key figures

Market cap £313M Small · P/S ratio 45.3 · Return on equity 0.4% · Return on assets (EBIT) −21.3% (5-year average) · Operating margin −1,470% · Revenue (TTM) $6.4M · Revenue growth (YoY) +92.2% · EPS growth (YoY) +61.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 17% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, PRTC screens richer than that median.

Fair Value

Bear £0.6200 Fair Value £0.8300 Bull £1.04
Price £1.26 · Downside -34.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 35
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 45
Distance to the 52-week high, does not count
New shares 74
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2019: revenue and profit before it include the divested business. Growth is measured afresh from 2019.
Revenue growth 1 year
+10.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,433.1% (2020) → −2,114.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PRTC screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare PureTech Health plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 6/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −34.1% · Below median
Profitability
Return on equity (12 months) 0.4% · Above median
Return on assets −21.0% · Above median
Net margin (12 months) 33.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 92.2% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.33× · Cheapest 25%
P/S (12 months) 65.22× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)2 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs PRTC
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs PRTC
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs PRTC
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs PRTC
argenx SE ARGX $977.58 $908.40 −7% vs PRTC
CSL Limited CSL A$204.54 A$181.40 −11% vs PRTC
Moderna, Inc MRNA $248.69 $158.70 −36% vs PRTC
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs PRTC
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs PRTC
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs PRTC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PureTech Health plc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PureTech Health plc Fair Value". https://www.fairvalue-calculator.com/stock/PRTC

Frequently asked questions

Is PureTech Health plc (PRTC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.8300 versus a price of £1.26, about 34% lower (overvalued).
What is the fair value of PRTC?
Our estimate for PureTech Health plc is £0.8300 (as of Nov 10, 2026), built from audited fundamentals. The current price: £1.26.
What is the quality score of PRTC?
PureTech Health plc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PureTech Health plc (PRTC)?
Our calculated price target is the estimate of £0.8300 (as of Nov 10, 2026). Cautious scenario £0.6200, optimistic scenario £1.04. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PureTech Health plc stock forecast for 2026?
Our estimate puts fair value at £0.8300, about 34% lower versus a price of £1.26 (overvalued). Cautious scenario £0.6200, optimistic scenario £1.04. The calculation is refreshed regularly with new filings.
What is the revenue of PureTech Health plc (PRTC)?
PureTech Health plc reported trailing-twelve-month revenue of about $6.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of PureTech Health plc (PRTC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PureTech Health plc it is £0.8300 per share (as of Nov 10, 2026), against a price of £1.26.
Is PureTech Health plc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PRTC trades above its calculated fair value: price £1.26, fair value £0.8300, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRTC?
No. The price is what the market pays today (£1.26); the fair value is what the company's own numbers justify (£0.8300). For PureTech Health plc the two are £0.4300 per share apart. That gap is exactly why we show both numbers side by side.
How much is PureTech Health plc worth?
The market values PureTech Health plc at about £313M (market capitalisation, as of Nov 10, 2026). Per share that is £1.26; our models calculate a fair value of £0.8300 per share.
What do the bullish and bearish scenarios say about PRTC?
Our models span a range for PureTech Health plc: cautious scenario £0.6200, base £0.8300, optimistic £1.04 per share (as of Nov 10, 2026, price £1.26). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PureTech Health plc (PRTC)?
Balance-sheet figures for PureTech Health plc (as of Nov 10, 2026): return on equity 0.4%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is PRTC from its 52-week high?
PureTech Health plc trades at £1.26, about 10% below its 52-week high of £1.40 and 17% above the low of £1.08 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of £0.8300 is for.
Which stocks are comparable to PureTech Health plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PureTech Health plc stock attractive at the current price?
The data as of Nov 10, 2026: price £1.26, calculated fair value £0.8300 (−34%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. PureTech Health plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PureTech Health plc (PRTC)?
The closing price on Nov 11, 2026 was £1.26. Our estimate is £0.8300, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PureTech Health plc right now?
The price sits above even our optimistic bull case (£1.04). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PureTech Health plc

How large is the market capitalisation of PureTech Health plc (PRTC)?
The market capitalisation of PureTech Health plc is £313M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PureTech Health plc (PRTC)?
The price-to-sales ratio of PureTech Health plc is 45.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of PureTech Health plc (PRTC)?
The return on equity (ROE) of PureTech Health plc is 0.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PureTech Health plc (PRTC)?
On an EBIT basis the return on assets of PureTech Health plc is −21.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PureTech Health plc (PRTC)?
The operating margin of PureTech Health plc is −1,470% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PureTech Health plc (PRTC)?
Revenue at PureTech Health plc is growing +92.2% versus a year earlier (3y avg +31.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PureTech Health plc (PRTC)?
Earnings per share at PureTech Health plc are growing +61.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does PureTech Health plc (PRTC) generate?
The free cash flow of PureTech Health plc is −$86.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does PureTech Health plc (PRTC) hold?
PureTech Health plc holds more cash than debt, $234M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch PureTech Health plc in the live analysis

One click puts PureTech Health plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.